PathWhiz

PathWhiz ID	Pathway	Meta Data
PW124564 View Pathway	metabolic Para-cresol Homo sapiens BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Rahil Doshi Created On: March 02, 2021 at 14:13 Last Updated: March 02, 2021 at 14:13
PW124551 View Pathway	drug action Ximelagatran Mechanism of Action Action Pathway Homo sapiens Ximelagatran is an anti-coagulant thrombin inhibitor that binds reversibly to the catalytic site and anion-binding exosite inhibiting the cleavage of fibrinogen into fibrin. Ximelagatran is used to treat heparin-induced thrombocytopenia as well as to prevent thrombosis. It is used in patients that are undergoing percutaneous coronary intervention or who have a risk in acute coronary syndromes caused by unstable angina or non-ST segment elevation. Thrombin is an important proteinase as it cleaves fibrinogen into fibrin monomers which help form the thrombus that forms the clot at the site of vascular injury. Because ximelagatran inhibits thrombin, clotting cannot form which is ideal for heart surgeries and some heart conditions. Ximelagatran should be monitored as it inhibits clotting so other injuries won't clot and it also can cause blood stagnation. Monitoring changes in hematocrit and blood pressure is extremely important when taking this drug. It is normally administered intravenously so that it is delivered to the site of action right away and can be controlled more easily. Ximelagatran is an anticoagulant drug used to prevent and treat blood clots, and was the first drug in the anticoagulant drug class to be able to be ingested orally. It was discontinued from distribution by its parent company AstraZeneca in 2006 as it was found to raise liver enzyme levels in patients and cause liver damage as a result. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Kristen Yee Created On: February 23, 2021 at 12:30 Last Updated: February 23, 2021 at 12:30
PW124550 View Pathway	drug action Argatroban Mechanism of Action Action Pathway Homo sapiens Argatroban is a selective thrombin inhibitor that binds reversibly to the catalytic site and anion-binding exosite inhibiting the cleavage of fibrinogen into fibrin. Unlike bivalirudin, argatroban is not a synthetic peptide but a derivative of L-arginine. Argatroban is used to treat heparin-induced thrombocytopenia as well as to prevent thrombosis. It is used in patients that are undergoing percutaneous coronary intervention or who have a risk in acute coronary syndromes caused by unstable angina or non-ST segment elevation. Thrombin is an important proteinase as it cleaves fibrinogen into fibrin monomers which help form the thrombus that forms the clot at the site of vascular injury. Because Argatroban inhibits thrombin, clotting cannot form which is ideal for heart surgeries and some heart conditions. Argatroban should be monitored as it inhibits clotting so other injuries won't clot and it also can cause blood stagnation. Monitoring changes in hematocrit and blood pressure is extremely important when taking this drug. It is normally administered intravenously so that it is delivered to the site of action right away and can be controlled more easily. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Kristen Yee Created On: February 23, 2021 at 12:20 Last Updated: February 23, 2021 at 12:20
PW124549 View Pathway	drug action Lepirudin Mechanism of Action Action Pathway Homo sapiens Lepirudin is a synthetic peptide thrombin inhibitor that binds reversibly to the catalytic site and anion-binding exosite inhibiting the cleavage of fibrinogen into fibrin. Lepirudin is used to treat heparin-induced thrombocytopenia as well as to prevent thrombosis. It is used in patients that are undergoing percutaneous coronary intervention or who have a risk in acute coronary syndromes caused by unstable angina or non-ST segment elevation. Thrombin is an important proteinase as it cleaves fibrinogen into fibrin monomers which help form the thrombus that forms the clot at the site of vascular injury. Because Lepirudin inhibits thrombin, clotting cannot form which is ideal for heart surgeries and some heart conditions. Lepirudin should be monitored as it inhibits clotting so other injuries won't clot and it also can cause blood stagnation. Monitoring changes in hematocrit and blood pressure is extremely important when taking this drug. It is normally administered intravenously so that it is delivered to the site of action right away and can be controlled more easily. Production of lepirudin by Bayer Pharmaceuticals has been stopped in 2012. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Kristen Yee Created On: February 23, 2021 at 12:09 Last Updated: February 23, 2021 at 12:09
PW124541 View Pathway	metabolic Phosphatidylcholine metabolism Homo sapiens BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Rahil Doshi Created On: February 22, 2021 at 18:15 Last Updated: February 22, 2021 at 18:15
PW124533 View Pathway	metabolic Drug Metabolism Template Homo sapiens BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Eponine Oler Created On: February 19, 2021 at 09:33 Last Updated: February 19, 2021 at 09:33
PW124525 View Pathway	drug action Doxycycline Homo sapiens BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Rahil Doshi Created On: February 11, 2021 at 14:41 Last Updated: February 11, 2021 at 14:41
PW124523 View Pathway	drug action Minocycline Homo sapiens BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Rahil Doshi Created On: February 11, 2021 at 14:17 Last Updated: February 11, 2021 at 14:17
PW124513 View Pathway	drug action Dasatinib Inhibition of BCR-ABL (New) Homo sapiens Dasatinib is a tyrosine kinase inhibitor used to treat chronic myelogenous leukemia (CML), a cancer characterized by increased and unregulated growth of white blood cells in the bone marrow and the accumulation of these cells in the blood and acute lymphoblastic leukemia . The cause of CML pathophysiology is the BCR-ABL fusion protein - the result of a genetic abnormality known as the Philadelphia chromosome in which Abelson Murine Leukemia viral oncogene homolog 1 (ABL1) translocates within the Breakpoint Cluster Region (BCR) gene on chromosome 22. BCR-ABL is a cytoplasm-targeted constitutively active tyrosine kinase that activates several oncogenic pathways which promote increased cell proliferation and survival including the MAPK/ERK Pathway, the JAK-STAT Pathway, and the PI3K/Akt pathway. For greater detail, refer to the pathway titled BCR-ABL Action in CML Pathogenesis. Dasatinib is able to bind ABL with greater affinity than Imatinib (25-55 times more potent). It is therefore administered to patients with Imatinib resistance. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Kristen Yee Created On: February 08, 2021 at 16:18 Last Updated: February 08, 2021 at 16:18
PW124512 View Pathway	signaling Jasmonic Acid Biosynthesis 1612785177 Arabidopsis thaliana BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Crystal Sparks Created On: February 08, 2021 at 04:53 Last Updated: February 08, 2021 at 04:53